Applies to most patients with one or two positive sentinel lymph nodes ...

The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

Upfront sentinel lymph node biopsy permitted the avoidance of axillary lymph node dissection in most patients with cN1 ...

Omitting completion axillary lymph node dissection does not increase risk for death for patients with clinically node-negative breast cancer, but it does significantly improve arm distress.Data from ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

Five-year OS was 94.4% with ALND omission vs 93.4% with completion ALND (HR 0.89), confirming non-inferiority; breast cancer–specific survival was similarly high in both arms. Inclusion of mastectomy ...

University of Queensland researchers have received a $3.1 million grant for a trial which could revolutionize endometrial cancer treatment. Research Director Professor Andreas Obermair at UQ's ...

Prospective Multicentric Randomized Study Comparing Periareolar and Peritumoral Injection of Radiotracer and Blue Dye for the Detection of Sentinel Lymph Node in Breast Sparing Procedures: FRANSENODE ...

Effect of bevacizumab on the risk of chemotherapy-associated anemia in cancer patients: A meta-analysis. Background: Arm lymphedema and limb morbidity in patients going through axillary lymph node ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...